2-Bromoethanol

2-Bromoethanol

SCHEMBL877195

[2H]C([2H])(O)C([2H])([2H])Br

nearest known ligand 0.00

Full drug profile on Sugi Atlas →

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
2-Bromoethanol SCHEMBL13916048 0.80
2-Bromoethanol SCHEMBL13916047 0.80
SCHEMBL1330915 0.79
SCHEMBL14477544 0.76
1,2-Dibromoethane SCHEMBL1448860 0.72
Ethylene Glycol SCHEMBL2307225 0.72
SCHEMBL2832683 0.65
SCHEMBL4957834 0.65
SCHEMBL160013 0.65
Dibromomethane SCHEMBL20701 0.65

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10273203-B2 Deuterated 3-methanesulfonylpropionitrile OLATEC THERAPEUTICS LLC (US) 2019-04-30 US claimed
US-20180290971-A1 DEUTERATED 3-METHANESULFONYLPROPIONITRILE OLATEC THERAPEUTICS, INC. 2018-10-11 US claimed
EP-4615838-A1 SUBSTITUTED BI-AND TRICYCLIC HSET INHIBITORS Merck Patent GmbH (DE) 2025-09-17 EP disclosed
US-12325708-B2 Adenosine 2 receptor antagonists NEKTAR THERAPEUTICS (US) 2025-06-10 US disclosed
WO-2024261234-A1 DEUTERATED ANALOGS OF SIRTUIN 6 MODULATOR IMU-856 IMMUNIC AG (DE) 2024-12-26 WO disclosed
US-20240316059-A1 PEPTIDE DRUG CONJUGATES ONCOPEPTIDES AB (SE) 2024-09-26 US disclosed
WO-2024099898-A1 SUBSTITUTED BI-AND TRICYCLIC HSET INHIBITORS MERCK PATENT GMBH (DE) 2024-05-16 WO disclosed
EP-4355370-A1 PEPTIDE DRUG CONJUGATES Oncopeptides Innovation AB (SE) 2024-04-24 EP disclosed
CN-117794580-A Polypeptide coupling medicine 肿瘤多肽有限公司 2024-03-29 CN disclosed
WO-2022263679-A1 PEPTIDE DRUG CONJUGATES ONCOPEPTIDES AB (SE) 2022-12-22 WO disclosed
US-20220235056-A1 ADENOSINE 2 RECEPTOR ANTAGONISTS NEKTAR THERAPEUTICS 2022-07-28 US disclosed
EP-2222166-B9 HETEROCYCLIC KINASE INHIBITORS CONCERT PHARMACEUTICALS INC (US) 2012-11-07 EP disclosed
EP-2222166-B1 HETEROCYCLIC KINASE INHIBITORS CONCERT PHARMACEUTICALS INC (US) 2012-06-27 EP disclosed
WO-2012040138-A2 NOVEL RADIOTRACER GE HEALTHCARE LIMITED (GB) 2012-03-29 WO disclosed
WO-2012040151-A2 ISOTOPIC CARBON CHOLINE ANALOGS GE HEALTHCARE LIMITED (GB) 2012-03-29 WO disclosed
WO-2012040133-A2 NOVEL PRECURSOR GE HEALTHCARE LIMITED (GB) 2012-03-29 WO disclosed
WO-2010033270-A1 DIBENZOTHIAZEPINE MODULATORS OF DOPAMINE, ALPHA ADRENERGIC, AND SEROTONIN RECEPTORS AUSPEX PHARMACEUTICALS, INC. (US) 2010-03-25 WO disclosed
US-20100069356-A1 DIBENZOTHIAZEPINE MODULATORS OF DOPAMINE, ALPHA ADRENERGIC, AND SEROTONIN RECEPTORS AUSPEX PHARMACEUTICALS, INC. (US) 2010-03-18 US disclosed
US-20100016365-A1 SUBSTITUTED 4-AMINO-PIPERIDINES AUSPEX PHARMACEUTICALS, INC. (US) 2010-01-21 US disclosed
US-20090149399-A1 HETEROCYCLIC KINASE INHIBITORS CONCERT PHARMACEUTICALS INC. (US) 2009-06-11 US disclosed